ADR incidence by drug regimen
| All regimens n=149 | HCQ n=20 | HCQ+AZ n=52 | HCQ+LPV/r n=22 | HCQ+AZ+LPV/r n=7 | HCQ regimens n=101 | REM n=48 | |
| Hepatobiliary disorders | 43 (28.9%) | 2 (10.0%) | 11 (21.2%) | 19 (86.4%) | 7 (100%) | 39 (38.6%) | 4 (8.3%) |
| ↑ Transaminases | 22 | 2 | 2 | 12 | 3 | 19 | 3 |
| ↑ Bilirubin | 5 | 0 | 0 | 3 | 1 | 4 | 1 |
| ↑ GGT | 5 | 0 | 1 | 3 | 1 | 5 | 0 |
| Liver cholestasis | 6 | 0 | 4 | 1 | 1 | 6 | 0 |
| Hepatotoxicity | 5 | 0 | 4 | 0 | 1 | 5 | 0 |
| Other | |||||||
| GI disorders | 28 (18.8%) | 4 (20.0%) | 6 (11.5%) | 12 (54.5%) | 6 (85.7%) | 28 (27.7%) | 0 |
| Diarrhoea | 16 | 1 | 1 | 9 | 5 | 16 | 0 |
| Nausea | 6 | 2 | 2 | 1 | 1 | 6 | 0 |
| Vomiting | 3 | 1 | 1 | 1 | 0 | 3 | 0 |
| Other GI disorders | 3 | 0 | 2 | 1 | 0 | 3 | 0 |
| Acute renal failure | 9 (6.0%) | 0 | 2 (3.8%) | 6 (27.3%) | 0 | 8 (7.9%) | 1 (2.1%) |
| Cardiac disorders | 8 (5.4%) | 2 (10.0%) | 4 (7.7%) | 0 | 2 (28.6%) | 8 (7.9%) | 0 |
| ↑QT interval | 6 | 2 | 3 | 0 | 1 | 6 | 0 |
| AF | 2 | 0 | 1 | 0 | 1 | 2 | 0 |
| Blood and lymphatic system | 2 (1.3%) | 0 | 0 | 2 (9.1%) | 0 | 2 (2.0%) | 0 |
| Thrombocytopenia | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Lymphopenia | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Skin and subcutaneous | 3 (2.0%) | 2 (10.0%) | 1 (1.9%) | 0 | 0 | 3 (3.0%) | 0 |
| Ocular | 2 (1.3%) | 0 | 1 (1.9%) | 1 (4.5%) | 0 | 2 (2.0%) | 0 |
| Nervous system | 1 (0.7%) | 0 | 0 | 0 | 0 | 0 | 1 (2.1%) |
| Other | 6 (4.0%) | 0 | 1 (1.9%) | 4 (18.2%) | 0 | 5 (5.0%) | 1 (2.1%) |
ADR, adverse drug reaction; AF, Atrial fibrillation; AZ, azithromycin; GGT, gamma-glutamyl transferase; GI, gastrointestinal; HCQ, hydroxychloroquine; LPV/r, lopinavir/ritonavir; REM, remdesivir.